ATE427118T1 - Verwendung von botulintoxin zur verbesserung der magenentleerung und/oder behandlung von gerd - Google Patents

Verwendung von botulintoxin zur verbesserung der magenentleerung und/oder behandlung von gerd

Info

Publication number
ATE427118T1
ATE427118T1 AT06801829T AT06801829T ATE427118T1 AT E427118 T1 ATE427118 T1 AT E427118T1 AT 06801829 T AT06801829 T AT 06801829T AT 06801829 T AT06801829 T AT 06801829T AT E427118 T1 ATE427118 T1 AT E427118T1
Authority
AT
Austria
Prior art keywords
botulintoxin
stomach emptying
treat gerd
improve stomach
gerd
Prior art date
Application number
AT06801829T
Other languages
English (en)
Inventor
Sheena Aurora
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Application granted granted Critical
Publication of ATE427118T1 publication Critical patent/ATE427118T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
AT06801829T 2005-08-24 2006-08-18 Verwendung von botulintoxin zur verbesserung der magenentleerung und/oder behandlung von gerd ATE427118T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11/211,311 US7910116B2 (en) 2005-08-24 2005-08-24 Use of a botulinum toxin to improve gastric emptying and/or to treat GERD

Publications (1)

Publication Number Publication Date
ATE427118T1 true ATE427118T1 (de) 2009-04-15

Family

ID=37496459

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06801829T ATE427118T1 (de) 2005-08-24 2006-08-18 Verwendung von botulintoxin zur verbesserung der magenentleerung und/oder behandlung von gerd

Country Status (6)

Country Link
US (1) US7910116B2 (de)
EP (1) EP1917032B1 (de)
AT (1) ATE427118T1 (de)
DE (1) DE602006006068D1 (de)
ES (1) ES2322872T3 (de)
WO (1) WO2007024672A1 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130071466A1 (en) * 2001-08-13 2013-03-21 Lipella Pharmaceuticals Inc. Methods and compositions for treating gastric disorders
US20150037402A1 (en) * 2001-08-13 2015-02-05 Lipella Pharmaceuticals, Inc. Methods and Compositions for Treating Gastric Disorders
US20040253274A1 (en) * 2003-06-11 2004-12-16 Allergan, Inc. Use of a clostridial toxin to reduce appetite
US20080092910A1 (en) * 2006-10-18 2008-04-24 Allergan, Inc. Apparatus and method for treating obesity using neurotoxins in conjunction with bariatric procedures
US8470337B2 (en) * 2008-03-13 2013-06-25 Allergan, Inc. Therapeutic treatments using botulinum neurotoxin
US8617571B2 (en) 2008-04-03 2013-12-31 Allergan, Inc. Suture line administration technique using botulinum toxin
US8357081B2 (en) 2008-12-05 2013-01-22 Onciomed, Inc. Method and apparatus for gastric restriction of the stomach to treat obesity
US8911346B2 (en) * 2008-12-05 2014-12-16 Onclomed, Inc. Gastric restriction devices with fillable chambers and ablation means for treating obesity
US20100249822A1 (en) * 2009-03-31 2010-09-30 Raj Nihalani Method and apparatus for treating obesity and controlling weight gain using adjustable intragastric devices
US8100932B2 (en) * 2009-03-31 2012-01-24 Onciomed, Inc. Method and apparatus for treating obesity and controlling weight gain using self-expanding intragastric devices
US20110118650A1 (en) * 2009-11-18 2011-05-19 Anteromed, Inc. Method and apparatus for treating obesity and controlling weight gain and absorption of glucose in mammals
AU2012282873B2 (en) 2011-07-08 2016-03-31 Allergan, Inc. Method for treatment of autonomic nervous system disorders
US10149893B2 (en) 2013-09-24 2018-12-11 Allergan, Inc. Methods for modifying progression of osteoarthritis
ES2952675T3 (es) 2013-10-22 2023-11-03 Lipella Pharmaceuticals Inc Administración de agentes mediante el uso de liposomas metaestables
US9457011B2 (en) * 2014-02-25 2016-10-04 Muslim D. Shahid Compositions and methods for the treatment of acid-related gastrointestinal disorders containing a dithiolane compound and a gastric acid secretion inhibitor

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9120306D0 (en) 1991-09-24 1991-11-06 Graham Herbert K Method and compositions for the treatment of cerebral palsy
US5437291A (en) * 1993-08-26 1995-08-01 Univ Johns Hopkins Method for treating gastrointestinal muscle disorders and other smooth muscle dysfunction
US5427291A (en) * 1993-09-21 1995-06-27 Smith; David S. Ski carrier and method employing same
US6974578B1 (en) * 1993-12-28 2005-12-13 Allergan, Inc. Method for treating secretions and glands using botulinum toxin
DE69428813T2 (de) 1993-12-28 2002-04-04 Allergan Sales Inc Verwendung von Botulinustoxin zur Behandlung von Spannungs-Kopfschmerz
US5766605A (en) * 1994-04-15 1998-06-16 Mount Sinai School Of Medicine Of The City University Of New York Treatment of autonomic nerve dysfunction with botulinum toxin
EP0758900B1 (de) * 1994-05-09 2002-04-10 BINDER, William J. Botulinumtoxin ZUR REDUKTION VON Migraine -KOPFSCHMERZEN
US5670484A (en) * 1994-05-09 1997-09-23 Binder; William J. Method for treatment of skin lesions associated with cutaneous cell-proliferative disorders
US5756468A (en) * 1994-10-13 1998-05-26 Wisconsin Alumni Research Foundation Pharmaceutical compositions of botulinum toxin or botulinum neurotoxin and methods of preparation
GB9508204D0 (en) * 1995-04-21 1995-06-07 Speywood Lab Ltd A novel agent able to modify peripheral afferent function
KR100544060B1 (ko) * 1997-07-15 2006-01-23 더 리젠트스 오브 더 유니버시티 오브 콜로라도 비뇨기과학 및 관련 부전증을 치료하기 위한 신경독요법의 용도
US6063768A (en) * 1997-09-04 2000-05-16 First; Eric R. Application of botulinum toxin to the management of neurogenic inflammatory disorders
US6358917B1 (en) * 1999-08-24 2002-03-19 Jean D. A. Carruthers Cosmetic use of botulinum toxin for treatment of downturned mouth
US6113915A (en) * 1999-10-12 2000-09-05 Allergan Sales, Inc. Methods for treating pain
US6265379B1 (en) * 1999-10-13 2001-07-24 Allergan Sales, Inc. Method for treating otic disorders
US6139845A (en) * 1999-12-07 2000-10-31 Allergan Sales, Inc. Method for treating cancer with a neurotoxin
US6143306A (en) * 2000-01-11 2000-11-07 Allergan Sales, Inc. Methods for treating pancreatic disorders
US6358513B1 (en) * 2000-02-15 2002-03-19 Allergan Sales, Inc. Method for treating Hashimoto's thyroiditis
US6319506B1 (en) * 2000-02-22 2001-11-20 Allergan, Sales, Inc. Method for treating hypercalcemia
US6464986B1 (en) * 2000-04-14 2002-10-15 Allegan Sales, Inc. Method for treating pain by peripheral administration of a neurotoxin
US6299893B1 (en) * 2000-04-17 2001-10-09 Marvin Schwartz Method to reduce hair loss and stimulate hair regrowth
US6306423B1 (en) * 2000-06-02 2001-10-23 Allergan Sales, Inc. Neurotoxin implant
US6306403B1 (en) * 2000-06-14 2001-10-23 Allergan Sales, Inc. Method for treating parkinson's disease with a botulinum toxin
US7737109B2 (en) * 2000-08-11 2010-06-15 Temple University Of The Commonwealth System Of Higher Education Obesity controlling method
US6423319B1 (en) * 2000-10-04 2002-07-23 Allergan Sales, Inc. Methods for treating muscle injuries
US6787517B1 (en) * 2000-12-29 2004-09-07 Allergan, Inc. Agent and methods for treating pain
US6623742B2 (en) 2001-09-17 2003-09-23 Allergan, Inc. Methods for treating fibromyalgia
US7238357B2 (en) 2002-11-05 2007-07-03 Allergan, Inc. Methods for treating ulcers and gastroesophageal reflux disease
US6838434B2 (en) * 2003-05-02 2005-01-04 Allergan, Inc. Methods for treating sinus headache
US8734810B2 (en) * 2003-10-29 2014-05-27 Allergan, Inc. Botulinum toxin treatments of neurological and neuropsychiatric disorders
US7897147B2 (en) * 2004-10-20 2011-03-01 Allergan, Inc. Treatment of premenstrual disorders

Also Published As

Publication number Publication date
WO2007024672A1 (en) 2007-03-01
US7910116B2 (en) 2011-03-22
DE602006006068D1 (de) 2009-05-14
US20070048334A1 (en) 2007-03-01
EP1917032A1 (de) 2008-05-07
ES2322872T3 (es) 2009-06-30
EP1917032B1 (de) 2009-04-01

Similar Documents

Publication Publication Date Title
ATE427118T1 (de) Verwendung von botulintoxin zur verbesserung der magenentleerung und/oder behandlung von gerd
PT2046373E (pt) Oxalato descarboxilase cristalizada e métodos de utilização
EA201490695A1 (ru) Слитые белки для лечения нарушений метаболизма
AR065033A1 (es) Metodos para prevenir y tratar trastornos neurodegenerativos
TW200736275A (en) Methods and compositions for treating allergic diseases
PH12013501010A1 (en) Methods of treating fgf21-associated disorders
BR112012008238A2 (pt) métodos para prevenção ou tratamento de sarcopenia e atrofia muscular em animais.
ATE480255T1 (de) Zusammensetzungen und verfahren zur kontrolle, prävention und behandlung von essstörungen
EA201370208A1 (ru) Формы рифаксимина и их применение
CO6660423A2 (es) Composiciones y métodos para tratar la enfermedad de gaucher
MX2012000034A (es) Metodos para el tratamiento o la prevencion de la fatiga.
MY148985A (en) 2-aminopyridine analogs as glucokinase activators
PH12012502187B1 (en) Antibodies to human gdf8
MX2011010908A (es) Anticuerpos anti-tnf-alfa y sus usos.
JO2576B1 (en) Antibodies
UA109878C2 (uk) Похідні ізохінолінону, фармацевтична композиція на їх основі (варіанти) та спосіб лікування захворювань (варіанти)
GB201318761D0 (en) Compounds for the treatment of neuropsychiatric disorders
UA109658C2 (xx) Антитіло проти cgrp
MX341883B (es) Composicion farmaceutica para el tratamiento y prevencion de canceres.
BRPI0712206A2 (pt) tratamento do agonista de melatonina
DK2282766T3 (da) Suturlinie-indgivelsesteknik med anvendelse af botulinumtoksiner
MY153062A (en) Methods of treating gastrointestinal disorders independent of the intake of food
SI2205244T1 (sl) Postopki dajanja N-(5-terc.-butil-izoksazol-3-il)-N'-(4-(7-(2-morfolin- 4-il-etoksi-)imidazo-2,1-b)-(1,3)-benzotiazol-2-il)-fenil)sečnine za zdravljenje proliferativne bolezni
MX2010007490A (es) Preparacion de derivados de sulfamida.
BRPI0908635B8 (pt) composto e/ou um sal farmaceuticamente aceitável do mesmo e composição farmacêutica

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties